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Abstract 
Background: Systemic inflammation contributes to obesity-associated 
complications. The short-pentraxin C-reactive-protein (CRP) is a validated 
inflammatory marker, while long-pentraxin-3 (PTX3) limits inflammation and is 
adaptively stimulated by proinflammatory cytokines in vitro. Severely obese 
patients [SO:BMI>40] have highest obesity-associated complications and 
increasingly undergo surgical treatment. SO-associated changes in plasma 
PTX3 and their interactions with systemic inflammation are however unknown. 
Objective: We sought to determine potential alterations in plasma PTX3 and 
their associations with changes in inflammatory markers prior to and following 
weight loss induced by laparoscopic Roux-en-Y gastric-bypass (LRYGB). 
Setting: University Hospital in Trieste, Italy. 
Methods: Plasma PTX3, CRP and cytokines including TNF-alpha and 
Interleukin-(IL)6 were measured in: 1) 24 individuals with severe, class III 
obesity (SO; age=42±1,F/M=18/6,BMI=45±1) before and 3,6,12 months after 
LRYGB; 2) age-, sex-matched normal-weight (L:n=56,BMI=22±0.2) or class I 
obese individuals (O:n=44,BMI=31.2±0.3). 
Results: SO, but not O, had higher plasma PTX3 compared to L, associated 
with highest proinflammatory cytokines and CRP (P<0.05 vs L-MO). In all 
subjects, plasma IL6 and TNF-alpha were associated positively with PTX3 
(P<0.05). Plasma CRP and proinflammatory cytokines declined during LRYGB-
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induced weight loss. In contrast, high PTX3 further increased and remained 
elevated (P<0.05 vs basal).  
Conclusions: Obesity level and energy balance modulate interactions between 
PTX3 and systemic inflammation. Elevated PTX3 is a novel, potentially 
adaptive alteration associated with proinflammatory cytokines in SO. Their 
differential changes conversely suggest circulating PTX3 as a novel negative 
inflammatory marker in SO undergoing LRYGB -induced weight loss. 
 
Keywords: obesity, LRYGB, Pentraxin3, inflammation 
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Introduction 
Obesity has a strong negative impact on morbidity and mortality, and severe, 
class III obesity [Body Mass Index (BMI) >40 kg/m2] is associated with 
highest disease-related complications rate and mortality rates (1-4). Gastric 
bypass is increasingly performed as an effective treatment to achieve 
sustained weight loss and reduce cardiometabolic risks associated with severe 
obesity (4). Importantly, obesity is also commonly associated with activated 
systemic inflammation, resulting in elevated circulating proinflammatory 
cytokines that include tumor necrosis factor-alpha (TNF-alpha) and interleukin-
6 (IL-6). Proinflammatory changes in circulating cytokines are thought to 
contribute to obesity-associated morbidity by favoring the onset of insulin 
resistance and cardiovascular dysfunction (5-7). Weight loss induced by caloric 
restriction or bariatric surgery may limit these alterations (7-12), and these 
effects may contribute to the positive effect of weight loss to reduce obesity-
associated morbidity. 
 
Pentraxins are acute phase reactants interacting with cytokines to modulate 
inflammation at both tissue and systemic levels (13), and both short and long 
components of the pentraxin family have been described (13). The short 
pentraxin C-reactive protein (CRP) is secreted by the liver and its plasma 
concentration is a validated marker of systemic inflammation also in obese 
individuals (14.15). On the other hand, the more recently-described long 
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pentraxin3 (PTX3) may be synthesized by several cell types including 
adipocytes, monocytes and endothelial cells (13,16). PTX3 has been interestingly 
reported to limit tissue damage and the inflammatory process in several 
disease models, including atherosclerosis, myocardial infarction, kidney injury 
and experimental carcinogenesis (17-20). Proinflammatory cytokines have been 
conversely reported to positively modulate PTX3 production in adipocytes (21), 
and this observation suggests a potential adaptive role of PTX3 in limiting 
inflammation activation in adipose tissue (16,17,21,22). Changes in circulating 
PTX3 in human obesity remain however controversial. Initial studies reported 
higher plasma PTX3 in obese than in normal weight individuals (23,24), but more 
recent general population reports suggest a negative impact of adiposity on 
plasma PTX3 (25-29). Consistent with the latter findings, one study reported that 
weight loss induced by lifestyle changes enhances circulating PTX3 (29). 
Importantly, the potential role of inflammatory mediators in modulating 
interactions between obesity and circulating PTX3 remains undefined. In 
addition, no studies are available on circulating PTX3 in severe, class III 
obesity, and its potential association with altered circulating cytokine profiles 
prior to and following surgically-induced weight loss in severely obese patients 
are unknown.  
 
In the current study, we therefore investigated changes in plasma PTX3, CRP 
and pro- (TNF-alpha, IL-6, IL-1beta) and anti-inflammatory cytokines 
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[interferon-gamma (IFN-gamma), IL-10] in individuals with severe class III 
obesity compared to class I obese or normal-weight individuals. We 
hypothesized that class III obesity would be associated with higher 
inflammation and higher circulating PTX3 compared to class I obesity and 
normal weight individuals. In addition, we investigated whether surgically-
induced weight loss would cause further increments in plasma PTX3, thereby 
potentially disrupting this putative association.  
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Materials and methods  
Study Protocol and Study Population 
The study protocol was approved by the Ethics Committee at Trieste University 
Hospital. All participants were given detailed oral and written information on 
study aims and risks, and they gave written consent before entering the study.  
 
Class III obese group and LRYGB 
A total of 24 patients with class III, severe obesity (SO; age 43±1 years, 
F/M=18/6) were recruited and underwent surgery at the General Surgery 
Division in Trieste University Hospital, and they were followed up at the 
Internal Medicine Obesity and Metabolic Syndrome outpatient Clinic. Patients 
who participated in all time points of follow-up were included for analyses and 
report. In all participants, clinical history was collected with complete physical 
examination. BMI was calculated as weight (in kilograms) divided by height (in 
meters) squared. Waist circumference was measured on bare skin during mid-
respiration at the natural indentation between the 10th rib and the iliac crest 
to the nearest 0.5 cm. Inclusion criteria were those internationally accepted for 
LRYGB surgery, with key role for morbid obesity and BMI >40 kg/m2. Exclusion 
criteria were those for LRYGB. In addition, patients with plasma creatinine 
>1.5 mg/dl were not included in this study since PTX3 has been reported to be 
associated with acute and chronic kidney disease (30). No patient included in 
this study was taking estrogen therapy that could potentially alter 
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inflammation, or had thyroid disease that could potentially alter energy 
balance and body weight. The diagnosis of thyroid disease was based on 
measurement of thyroid hormones and thyroid-stimulating hormone (TSH) 
during routine screening before LRYGB surgery, that led to the exclusion of one 
subject from the current study. Type 2 diabetes mellitus was diagnosed based 
on clinical history or plasma glucose concentration > 126 mg/dl or hemoglobin 
A1c > 6.5% during pre-surgery screening. Diabetes prevalence was 4 out of 
24 patients in the severely obese group. 
 
For patients undergoing LRYGB, one blood sample was collected 1-2 weeks 
before surgery under 10-h fasted conditions; plasma was stored at -80 °C until 
biochemical and hormonal measurements were performed. Additional 
measurements and sampling were taken under identical conditions at 3, 6 and 
12 months after surgery.  
 
The LRYGB procedure was performed laparoscopically in all subjects as 
previously described (31). Briefly, a liver retractor was used to move the left 
lobe laterally and visualize the hiatus and the lesser curve. A 34-French 
orogastric tube was inserted by the anaesthesiologist to calibrate the future 
gastric pouch (50-70ml). The dissection began between the first and second 
vascular arcades on the lesser curvature and a laparoscopic linear stapler was 
fired. The first suture line was horizontal, the second line ran parallel to the 
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oesophagus towards the angle of His. Once the gastric pouch was completely 
separated from the bypassed stomach, the omentum and the transverse 
mesocolon were lifted upwards and the ligament of Treitz was identified. The 
biliary limb was measured 100 cm distal to the ligament of Treitz and the 
alimentary limb was measured up to 120 cm. Gastro-entero anastomosis 
between gastric pouch and alimentary limb was peformed. Then, the 
jejunojejunostomy was created between the alimentary and biliary limbs. An 
intraoperative test with coloured water irrigation through a naso-gastric tube 
was routinely performed to verify gastro-jejunal anastomosis integrity. 
 
Normal weight and class I obese control groups 
Normal weight (N; n=56) and class I obese (O; n=44) individuals who did not 
undergo LRYGB were also recruited for the study as control groups. Class I 
obese individuals had not undertaken weight-reducing dietary treatments for 
at least 12 months prior to the study. They were weight-stable, defined as 
self-reported lack of weight changes greater than 3% of current body weight in 
the previous six months. In addition to sampling for hormone measurements 
for cross-sectional comparisons, they underwent a routine examination and 
biochemical work-up to assess their metabolic profile. No patients in these 
groups had plasma creatinine > 1.5 mg/dl, was taking estrogen therapy or had 
thyroid disease based on plasma thyroid hormones and TSH concentration. 
Class I obese individuals had BMI comparable with LRYGB patients at 12- 
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month follow-up, but they were weight-stable and had not undergone bariatric 
surgery procedures. Pentraxin and cytokine profiles at the end of the 12-
month follow-up period was therefore also compared with that of the class I 
obese control individuals alone, to assess the potential impact of LRYGB 
independently of major anthropometric and metabolic confounding variables. 
 
Plasma analyses 
Plasma glucose, total and high-density lipoprotein cholesterol, and plasma 
triglycerides were measured using standard methods. Plasma insulin was 
measured by enzyme-linked immunosorbent assay (Insulin Human 
Ultrasensitive ELISA; DRG Instruments, Marburg, Germany). Insulin sensitivity 
was calculated  by the homeostatic model assessment (HOMA) (31) using the 
following formula: HOMA = (FPG x FPI)/22.5, where FPG and FPI are fasting 
plasma glucose (mmol) and fasting plasma insulin (mU/ml), respectively. 
Plasma PTX3 (Human Pentraxin3 /TSG-14ELISA System Perseus Proteomics 
Inc., Tokyo, Japan) (27) and C-reactive protein (CRP) (High sensitivity c-
reactive protein, Diagnostics Biochem Canada Inc London, Ontario, Canada) 
were measured using commercially available ELISA kit. Plasma cytokines were 
measured with multiplex high-throughput xMAP technology, using analyte 
detection combinations commercialy available and validated by the producer 
(MILLIPLEX High Sensitivity Human Cytokine Magnetic Bead Panel, Millipore, 
Billerica, MA, USA).  
 11 
 
Statistical analysis 
The StatView software was used for all statistical analyses. Time effects for 
each variable in the LRYGB group were analyzed using ANOVA and paired t-
test. Differences between non- LRYGB and LRYGB individuals were analyzed 
using ANOVA and post-hoc tests for multiple comparisons. Linear and multiple 
regression analyses were used to determine associations between variables. 
Due to non-normal data distribution, log-transformed values for HOMA, PTX3, 
CRP and all cytokines were used for analyses. P values < 0.05 were considered 
statistically significant.  
 
Results 
Basal 
BMI, plasma insulin, glucose, HOMA index in N, O and SO (Table 1) – The 
three groups were comparable for age and sex. Before LRYGB, SO patients had 
highest BMI and waist circumference by design (Table 1). These alterations 
were associated with highest plasma insulin, glucose, and HOMA index 
compared to both normal weight and class I obese individuals (Table 1).  
Plasma cytokines, CRP and PTX3 in N, O and SO (Figures 1,2) - IL-10 and IFNg 
were comparably lower (P<0.05)  in O and SO than in Lean individuals (Figure 
1a). In contrast, TNF-alpha and IL-6 were comparable in O and N groups while 
they were selectively higher in SO (P<0.05 vs Lean-MO) (Figure 1b). The 
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TNFalpha-to-IL10 ratio consequently increased progressively from N to O to SO 
(all P<0.05) (Figure 1c). These changes were associated with stepwise 
increments from N to O to SO in the plasma concentration of pro-inflammatory 
short pentraxin CRP (all P<0.05). On the other hand, plasma PTX3 was 
comparable in N and O groups, while it was selectively higher in SO individuals 
(P<0.05 vs N-O) (Figure 2). 
Associations between plasma PTX3, cytokines and clinical variables (Table 2, 
Figure 3) – In linear regression analysis in all subjects (n=124) PTX3 was 
positively associated with BMI, plasma insulin, HOMA index, CRP (Table 2) and 
proinflammatory IL6 and TNFalpha (Figure 3). In multiple regression analyses, 
plasma IL6 and TNFalpha remained positively associated with PTX3 in models 
including BMI and HOMA index (Table 2). 
 
LRYGB 
BMI and biochemical profile in SO prior to and following LRYGB (Table 3) - 
LRYGB expectedly led to a substantial, progressive reduction in BMI and waist 
circumference, with substantial excess BMI loss (EBMIL), total weight body 
loss (TWBL), excess weight loss (EWL). These changes were also expectedly  
associated with lower plasma glucose and plasma insulin, resulting in major 
reduction in HOMA index (Table 3). No early reductions were observed for 
plasma total cholesterol and triglycerides, whereas HDL cholesterol was lower 
1 month after LRYGB than prior to LRYGB. Lowering of plasma triglycerides 
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with higher HDL cholesterol was observed 6 and 12 months after LRYGB (Table 
3). 12 months after LRYGB, patients had BMI, waist circumference, plasma, 
free fatty acids, and HOMA comparable to those in O individuals that had not 
undergone surgery (all P = not significant).  
Plasma cytokines, CRP and PTX3 in SO following LRYGB (Table 3, Figures 4,5) 
- LRYGB did not alter plasma cytokine concentrations during the first six 
months of follow-up. At the 12-month follow-up, plasma TNF-alpha, IL-6, IL-
1beta as well as IFNgamma were lower compared to basal values prior to 
LRYGB (Figure 4a-e). The TNFalpha-IL10 ratio was also lower at the 12-month 
follow-up compared to basal value (P<0.05, 12-month vs t=0) (Figure 4f). 
Plasma CRP underwent earlier, progressive reduction from the first follow-up 
evaluation (P<0.05) (Figure 5). In contrast, high plasma PTX3 observed prior 
to LRYGB further increased at the first follow-up and remained comparably 
elevated at subsequent measurements compared to basal value (Figure 5). No 
statistically significant associations were observed between changes in PTX3 
over the 12-month follow-up and corresponding changes in BMI, CRP and 
cytokines (not shown). All results at all time points are from 24 patients 
enrolled in the study. 
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Discussion 
The current study provides novel information on the impact of severe obesity 
on plasma PTX3, and on its potential associations with inflammatory markers 
prior to and following gastric bypass-induced weight loss. In particular, we 
here demonstrated that: 1) associations between PTX3 and systemic 
inflammation are modulated by obesity level and changes in energy balance; 
2) patients with severe obesity have high plasma PTX3 compared to both class 
I obese and normal weight individuals, associated with increasing pro-
inflammatory cytokines; 3) LRYGB-induced weight loss profoundly alters 
pentraxin-cytokine patterns, with further increments in circulating PTX3 in the 
presence of lower inflammation activators and markers. 
 
BASAL 
Under basal conditions, circulating PTX3 was higher in severe, class III obesity 
than in both normal weight and class I obese individuals. This alteration was 
associated with higher circulating inflammatory markers, and plasma IL6 and 
TNFalpha were positive predictors of PTX3 in the whole study population. The 
current results therefore indicate that PTX3 may represent a marker of 
systemic inflammation in class III obese individuals. In vitro studies notably 
demonstrated a direct stimulatory effect of TNF-alpha on PTX3 production in 
adipocytes (21). The current findings are therefore in agreement with the 
hypothesis that higher circulating pro-inflammatory cytokines directly 
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contribute to higher circulating PTX3 in class III obese individuals, and this 
putative effect could be aimed at limiting inflammation activation at adipose 
tissue and systemic level (16-18). It should be pointed out that these combined 
observations could contribute to explain existing controversial reports on the 
impact of obesity on circulating PTX3, since high or preserved circulating PTX3 
were notably mostly reported in obese patients affected by chronic 
complications that commonly involve inflammation activation, such as 
metabolic syndrome and atherosclerosis (23) or diabetes (28). Additional studies 
with simultaneous measurement of PTX3 and inflammatory markers in obese 
individuals with various levels of obesity-associated complications are needed 
to further confirm this interaction.  
 
SURGERY 
LRYGB-induced weight loss was associated with profoundly altered patterns of 
circulating pentraxins and cytokines. Early reduction in body mass lead to early 
lowering of CRP, although reductions in pro-inflammatory cytokines were only 
observed 6-12 months after surgery. At variance with CRP, high basal PTX3 
further increased and remained elevated throughout the 12 month follow-up 
period. Surgically-induced weight loss is therefore associated with differential 
changes in plasma CRP, cytokines and PTX3 concentrations. At variance with 
pre-surgical conditions, the current findings indicate that PTX3 may become a 
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clinically relevant negative marker of systemic inflammation in the increasing 
population of severely obese patients undergoing LRYGB. 
 
Higher circulating PTX3 following LRYGB-induced weight loss is in good 
agreement with results from a general population cohort undergoing lifestyle-
induced weight reduction (29), and these combined results are consistent with 
the concept that negative energy balance enhances circulating PTX3 in obese 
humans. The current study design does not allow to directly identify underlying 
mechanisms for this effect, but the time-course of PTX3 modifications suggests 
that different factors could have contributed at different time points. Although 
no statistically significant associations were observed between overall changes 
in circulating PTX3 and changes in body weight markers at one-year follow-up, 
the initial rapid, substantial weight loss could have facilitated early PTX3 
increments through yet undefined mechanisms. Circulating pro-inflammatory 
cytokines were persistently elevated at early follow-up, and they could have 
played a relevant permissive role in the rise of plasma PTX3. Sustained PTX3 
elevation despite declining pro-inflammatory cytokines at later stages of 
follow-up could have been mediated at least in part by increasing HDL-
cholesterol and by the relative increase in anti-inflammatory cytokines, 
including IL-10. Both HDL-cholesterol and IL-10 were indeed previously 
reported to stimulate PTX3 production from non-adipose sources in 
experimental models (32,33), and they could have therefore prevented a decline 
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in circulating PTX3 despite declining pro-inflammatory mediators. On the other 
hand, available knowledge does not support a role of lower plasma glucose and 
insulin resistance in LRYGB-induced PTX3 elevation, since insulin resistance 
and high plasma glucose may indeed increase circulating PTX3 in humans (34). 
Further studies are needed to confirm these hypotheses and to identify 
potential additional mechanisms underlying PTX3 elevation during surgically-
induced negative energy balance and weight loss. 
 
The LRYGB-induced decline in biomarkers of systemic inflammation is well-
established in available literature (9-12). Our results identify a time-course of 
changes in pro- and anti-inflammatory cytokines with potentially relevant 
pathophysiological implications. In particular, as stated above lack of early 
decline in pro-inflammatory cytokines could have played a permissive role in 
early increments in circulating PTX3. Importantly, cytokine profiles at 12-
month follow-up were superimposable to those in matched individuals with 
class I obesity who had not undergone bariatric surgery, thereby confirming 
the effectiveness of LRYGB in normalizing systemic inflammatory responses.  
 
Overall, the observed results provide novel information on the impact of severe 
obesity and LRYGB on circulating PTX3, its interactions with systemic 
inflammation and potential underlying regulatory mechanisms. It should be 
pointed out that the study sample does not allow to directly extend these 
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findings to potentially important patient groups, including older people and 
people with type 2 diabetes. Additional studies will be necessary to directly 
confirm the current conclusions under these clinical conditions.  
 
Conclusion: the current study demonstrated that interactions between PTX3 
and systemic inflammation are modulated by obesity level and changes in 
energy balance. High plasma PTX3 is a novel, potentially adaptive alteration 
associated with elevated proinflammatory cytokines in SO. Opposite changes in 
PTX3 and systemic inflammation suggest circulating PTX3 as a novel negative 
inflammation marker in severely obese individuals undergoing LRYGB -induced 
weight loss. 
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Figure Legend: 
Figure 1: a) Plasma interferon-gamma (IFNg) and Interleukin-10 (IL10); b) 
plasma Interleukin-1beta (IL1beta), Interleukin-6 (IL6) and TNF-alpha; c) 
plasma TNF-alpha to IL10 ratio in Normal weight, Class I Obese and Class III 
Obese groups. *: P<0.05 vs Normal weight, **: P<0.05 vs Normal weight 
and Class I Obese by ANOVA and Wilcoxon test.  
Figure 2: a) Plasma C-reactive Protein (CRP); b) plasma Pentraxin-3 (PTX3) 
in Normal weight, Class I Obese and Class III Obese groups. *: P<0.05 vs 
Normal weight, **: P<0.05 vs Normal weight and Class I Obese by ANOVA 
and Wilcoxon test. 
Figure 3: Correlations between plasma PTX3 and plasma TNF-alpha or IL-6 
in the three study groups (n=124). 
Figure 4: Changes in plasma (a) Interferon-gamma (IFN-gamma), (b) 
Interleukin-10 (IL10), (c) Interlleukin-1beta (IL1beta), d) Interleukin-6 
(IL6), e) TNF-alpha and f) TNF-alpha to IL10 ratio over 12 months of 
observation in severely obese patients undergoing gastric bypass (LRYGB) 
surgery (n=24 at all time points), compared to moderately obese patients 
not treated with LRYGB (Ob-Non LRYGB). *: P<0.05 vs 0 by Paired t-test (0 
vs follow-up time points) or ANOVA and post-hoc tests (0 vs Class I Obese). 
No statistically significant differences were observed for any variable 
between 0 and 3-month or between 0 and 6-month follow-up by Paired t-
test. No statistically significant differences were also observed for any 
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variable between 12-month and Class I Obese – No-LRYGB by ANOVA and 
post-hoc tests. 
Figure 5: Changes in plasma a) CRP and b) PTX3 over 12 months of 
observation in severely obese patients undergoing gastric bypass surgery 
(LRYGB) (n=24 at all time points), compared to Class I Obese patients not 
treated with LRYGB (Class I Obese – No-LRYGB). *: P<0.05 vs 0 and Class I 
Obese; **: P<0.05 vs 0, 3-month, 12-month; ***; P<0.05 vs 0, 3-month, 
6-month, Class I Obese by Paired t-test (0 vs follow-up time points) or 
ANOVA and post-hoc tests (0 vs Class I Obese). 
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Table 1: Gender, age, body mass index (BMI), waist circumference (WC), plasma 
total and HDL-cholesterol (Chol), plasma triglycerides, systolic (SBP) and diastolic 
(DBP) blood pressure, plasma glucose and insulin, homeostasis model assessment 
of insulin resistance (HOMA-IR) in the Normal weight (Normal), Class I Obese 
(Obese) and Class III Obese patient groups. In each line, *: P<0.05 vs Normal; **: 
P<0.05 vs Normal and Obese by ANOVA and post-hoc tests. 
_____________________________________________________________ 
             
        Normal               Obese         Class III Obese 
              
Gender (M/F)          38/18                 30/14       18/6  
Age (years)    43±1          44±1        43±1  
BMI (kg/m2)                22±0.2          31.2±0.3 *   43.1±0.1 ** 
WC (cm)                                 80±1                  99±1 *      139±2 ** 
Total-Chol (mg/dl)                190±5          212±6 *     214±5 * 
HDL-Chol (mg/dl)            52±1           47±1 *       48±1 * 
Triglycerides (mg/dl)            76±3                134±8 *     164±8 ** 
SBP (mmHg)                  126±2                 128±2      134±2* 
DBP (mmHg)            78±1            85±1*       90±1** 
Glucose (mMol)                87±1          92±1*          103±3** 
Insulin (μU/ml)                 5.1±0.2         6.6±0.3 *   20.5±1.4 ** 
HOMA-IR               1.01±0.04      1.47±0.07 *   5.41±0.44 ** 
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Table 2 – Linear and multiple regression analyses 
a) Linear regression analysis between PTX3 as dependent variable and age, Body 
Mass Index (BMI), waist circumference (WC), plasma Total and HDL-cholesterol 
(Chol), triglycerides, systolic (SBP) and diastolic (DBP) blood pressure, plasma 
glucose, insulin, HOMA index, Interferon gamma (IFNgamma), Interleukin (IL)10, 
IL1beta, TNFalpha to IL10 ratio, and plasma C-reactive protein (CRP) in all 
individuals (n=124). 
b) Multiple regression analyses (t-value) between PTX3 (dependent variable) and 
each inflammatory marker in a model also including BMI and HOMA index, in all 
individuals (n=124). Similar results were observed when plasma insulin was used 
instead of HOMA index (not shown). 
*: P<0.05; **: P<0.01. 
 
a)      PTX3       
              r                
Age (years)     0.109        
BMI (kg/m2)             0.342*        
WC (cm)            -0.168 
Total-Chol (mg/dl)                   -0.158             
HDL-Chol (mg/dl)             0.075             
Triglycerides (mg/dl)                   -0.128             
SBP (mmHg)           -0.181 
DBP (mmHg)           -0.138 
Glucose (mg/dl)              0.087             
Insulin (µU/ml)              0.373**             
HOMA     0.315* 
IFNgamma (pg/ml)                    0.160             
IL10 (pg/ml)            0.111 
IL1beta (pg/ml)            0.147 
TNFalpha-IL10 ratio   0.150 
CRP (mg/L)                     0.352*      
 
b)                        PTX3       
          t 
IL6 (pg/ml)         2.161*                
TNFalpha (pg/ml)           1.893*                
CRP (mg/L)                 0.051                 
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Table 3: Body mass index (BMI), excess BMI loss (EBMIL), total weight body loss 
(TWBL), excess weight loss (EWL), waist circumference (WC), plasma glucose and 
insulin, homeostasis model assessment of insulin resistance (HOMA-IR), plasma 
total and HDL cholesterol (Chol), triglycerides (Tg) and systolic (SBP) and diastolic 
(DBP) blood pressure in Class III Obese individuals before LRYGB (0) and during a 
12-month follow-up period with evaluation at 3,6,12 months from surgery (3-
month, 6-month, 12-month; n=24 at all time points).  
 
$ Denotes a statistically significant decline (P<0.05) for the corresponding variable 
from 0 to 12 months by ANOVA. *: P<0.05 vs 0; **: P<0.05 vs 0 and 3-month; 
***: P<0.05 vs 0, 3-month and 6-month by paired t-test. 
__________________________________________________________________
__________________________ 
            0           3-month          6-
month          12-month                
 
BMI (kg/m2)*        43.1±0.1         37.2±1.1 *       
 33.2±1.2 **          30.9±1.2 ***  
EBMIL (kg/m2)*         0.0±0.0         44.3±2.1 *       
 64.3±3.1 **          79.0±3.0 ***  
TBWL (%)*            0.0±0.0         19.0±0.8 *       
 27.5±1.0 **          34.6±1.1 ***   
EWL (%)*            0.0±0.0         43.5±2.2 *       
 63.6±3.2 **          79.0±3.1 ***  
WC (cm)*                              139±2          117±2 *             
109±3 **             100±3 ***    
Glucose (mMol)*          101±3                    89±2 *        
85±1**              86±2 **           
Insulin (μU/ml)*        20.9±1.5            8.8±1.1 *            7±0.7 
**          5.8±0.4 **               
HOMA-IR*              5.41±0.44                 1.96±0.25 *              
1.50±0.16 **          1.26±0.1 ***                
Total-Chol (mg/dl)         211±5                185±8 *                      
184±9 *              192±11 *  
HDL-Chol (mg/dl)                 48±1                 44±1 *                        
49±1                53±1 ***    
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Triglycerides (mg/dl)*        151±7                      124±9 *            
100±9 **             82±6 ***   
SBP (mmHg)*         134±2                131±3                      
126±3 **             125±3 **        
DBP (mmHg)*          90±1                 88±3                82±2 
**               83±2 **           
 
 
